drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00418 | DB09330 | 536 | 985 | [
"DDInter1650",
"DDInter1352"
] | Secobarbital | Osimertinib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
536,
24,
985
]
],
[
[
536,
62,
168
],
[
168,
23,
985
]
],
[
[
536,
24,
112
],
[
112,
23,
985
]
],
[
[
536,
24,
1478
],
[
1478,
2... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[... | Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Me... |
DB01215 | DB09420 | 1,418 | 1,074 | [
"DDInter677",
"DDInter953"
] | Estazolam | Iodide I-123 | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1418,
24,
1074
]
],
[
[
1418,
24,
516
],
[
516,
24,
1074
]
],
[
[
1418,
1,
902
],
[
902,
24,
1074
]
],
[
[
1418,
40,
523
],
[
523,
... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
... | Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Estazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that c... |
DB00334 | DB01254 | 867 | 1,213 | [
"DDInter1326",
"DDInter484"
] | Olanzapine | Dasatinib | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
867,
24,
1213
]
],
[
[
867,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
867,
7,
8153
],
[
8153,
46,
1213
]
],
[
[
867,
18,
20057
],
[
20057,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Olanzapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Olanzapine (Compound) upregulates ADCK3 (Gene) and ADCK3 (Gene) is upregulated by Dasatinib (Compound)
Olanzapine (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is downregulated by Dasatinib (Compound)
Olanzapine may ... |
DB11978 | DB12941 | 124 | 466 | [
"DDInter822",
"DDInter481"
] | Glasdegib | Darolutamide | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
124,
23,
466
]
],
[
[
124,
64,
1622
],
[
1622,
23,
466
]
],
[
[
124,
63,
34
],
[
34,
23,
466
]
],
[
[
124,
24,
283
],
[
283,
23,... | [
[
[
"Glasdegib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voriconazole"
],
[
"Voriconazo... | Glasdegib may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir ma... |
DB00604 | DB04843 | 1,425 | 1,511 | [
"DDInter385",
"DDInter1149"
] | Cisapride | Mepenzolate | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1425,
24,
1511
]
],
[
[
1425,
25,
675
],
[
675,
24,
1511
]
],
[
[
1425,
24,
1192
],
[
1192,
24,
1511
]
],
[
[
1425,
25,
1605
],
[
1605... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dex... | Cisapride may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Gl... |
DB06210 | DB14520 | 72 | 1,229 | [
"DDInter631",
"DDInter1785"
] | Eltrombopag | Tetraferric tricitrate decahydrate | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
72,
24,
1229
]
],
[
[
72,
24,
1292
],
[
1292,
24,
1229
]
],
[
[
72,
24,
627
],
[
627,
25,
1229
]
],
[
[
72,
24,
1292
],
[
1292,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"D... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Eltrombopag may cause a moderate interaction that could exacerbate diseases when take... |
DB00196 | DB00393 | 600 | 854 | [
"DDInter743",
"DDInter1295"
] | Fluconazole | Nimodipine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Moderate | 1 | [
[
[
600,
24,
854
]
],
[
[
600,
24,
84
],
[
84,
40,
854
]
],
[
[
600,
6,
8374
],
[
8374,
45,
854
]
],
[
[
600,
21,
28936
],
[
28936,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine (Compound) resembles Nimodipine (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nimodipine (Compound)
Fluconazole (Compound) causes Hyperhidrosis (Side Effect) and ... |
DB00675 | DB05294 | 888 | 1,069 | [
"DDInter1744",
"DDInter1917"
] | Tamoxifen | Vandetanib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
888,
25,
1069
]
],
[
[
888,
6,
7526
],
[
7526,
45,
1069
]
],
[
[
888,
7,
2065
],
[
2065,
45,
1069
]
],
[
[
888,
21,
29343
],
[
29343,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"FMO1"
],
[
"FMO1",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
... | Tamoxifen (Compound) binds FMO1 (Gene) and FMO1 (Gene) is bound by Vandetanib (Compound)
Tamoxifen (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Vandetanib (Compound)
Tamoxifen (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib ... |
DB01069 | DB08883 | 401 | 1,597 | [
"DDInter1533",
"DDInter1428"
] | Promethazine | Perampanel | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
401,
24,
1597
]
],
[
[
401,
24,
609
],
[
609,
23,
1597
]
],
[
[
401,
63,
100
],
[
100,
24,
1597
]
],
[
[
401,
24,
649
],
[
649,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Perampanel
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Bromphenira... |
DB00992 | DB05294 | 842 | 1,069 | [
"DDInter1182",
"DDInter1917"
] | Methyl aminolevulinate (topical) | Vandetanib | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
842,
24,
1069
]
],
[
[
842,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
842,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
842,
24,
1247
],
[
1247... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erl... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Methyl aminolevulinate (Compound) ca... |
DB00242 | DB08895 | 1,064 | 976 | [
"DDInter392",
"DDInter1825"
] | Cladribine | Tofacitinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1064,
25,
976
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
976
]
],
[
[
1064,
24,
1017
],
[
1017,
63,
976
]
],
[
[
1064,
25,
998
],
[
998,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatini... |
DB00727 | DB00782 | 685 | 1,123 | [
"DDInter1304",
"DDInter1535"
] | Nitroglycerin | Propantheline | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure ex... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Minor | 0 | [
[
[
685,
23,
1123
]
],
[
[
685,
21,
28681
],
[
28681,
60,
1123
]
],
[
[
685,
23,
537
],
[
537,
63,
1123
]
],
[
[
685,
63,
999
],
[
999,
... | [
[
[
"Nitroglycerin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
],
[
[
"Nitroglycerin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} ... | Nitroglycerin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Propantheline (Compound)
Nitroglycerin may cause a minor interaction that can limit clinical effects when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when... |
DB00661 | DB11967 | 122 | 710 | [
"DDInter1928",
"DDInter210"
] | Verapamil | Binimetinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
122,
24,
710
]
],
[
[
122,
24,
1593
],
[
1593,
24,
710
]
],
[
[
122,
63,
883
],
[
883,
24,
710
]
],
[
[
122,
25,
1406
],
[
1406,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitini... |
DB00019 | DB00848 | 1,257 | 281 | [
"DDInter1405",
"DDInter1044"
] | Pegfilgrastim | Levamisole | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Moderate | 1 | [
[
[
1257,
24,
281
]
],
[
[
1257,
24,
599
],
[
599,
24,
281
]
],
[
[
1257,
24,
4
],
[
4,
63,
281
]
],
[
[
1257,
25,
1064
],
[
1064,
2... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamisole"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine m... |
DB00420 | DB09043 | 508 | 135 | [
"DDInter1532",
"DDInter36"
] | Promazine | Albiglutide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
508,
24,
135
]
],
[
[
508,
63,
1647
],
[
1647,
23,
135
]
],
[
[
508,
24,
870
],
[
870,
24,
135
]
],
[
[
508,
63,
176
],
[
176,
2... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludroco... |
DB00332 | DB11160 | 1,089 | 337 | [
"DDInter970",
"DDInter1459"
] | Ipratropium | Phenyltoloxamine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
1089,
24,
337
]
],
[
[
1089,
24,
820
],
[
820,
24,
337
]
],
[
[
1089,
35,
19
],
[
19,
24,
337
]
],
[
[
1089,
63,
701
],
[
701,
2... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interactio... |
DB01222 | DB14730 | 617 | 1,412 | [
"DDInter246",
"DDInter264"
] | Budesonide | Calaspargase pegol | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
617,
24,
1412
]
],
[
[
617,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
617,
63,
1274
],
[
1274,
24,
1412
]
],
[
[
617,
40,
251
],
[
251,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
... | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen ... |
DB01234 | DB11613 | 1,220 | 1,519 | [
"DDInter513",
"DDInter1924"
] | Dexamethasone | Velpatasvir | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Major | 2 | [
[
[
1220,
25,
1519
]
],
[
[
1220,
24,
1135
],
[
1135,
23,
1519
]
],
[
[
1220,
25,
594
],
[
594,
24,
1519
]
],
[
[
1220,
23,
1384
],
[
1384... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Nalo... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Velpatasvir
Dexamethasone may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause... |
DB00046 | DB13873 | 1,179 | 1,534 | [
"DDInter940",
"DDInter719"
] | Insulin lispro | Fenofibric acid | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Moderate | 1 | [
[
[
1179,
24,
1534
]
],
[
[
1179,
24,
959
],
[
959,
24,
1534
]
],
[
[
1179,
63,
305
],
[
305,
24,
1534
]
],
[
[
1179,
24,
959
],
[
959,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Asparagina... |
DB00350 | DB01240 | 1,214 | 885 | [
"DDInter1226",
"DDInter657"
] | Minoxidil | Epoprostenol | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1214,
24,
885
]
],
[
[
1214,
24,
1061
],
[
1061,
1,
885
]
],
[
[
1214,
23,
402
],
[
402,
23,
885
]
],
[
[
1214,
24,
1450
],
[
1450,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Minoxidil may cause a minor interaction that can limit clinical effects when taken with Tadalafil and Tadalafil may cause a minor interaction that can limi... |
DB01309 | DB01403 | 1,254 | 9 | [
"DDInter933",
"DDInter1175"
] | Insulin glulisine | Methotrimeprazine | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1254,
24,
9
]
],
[
[
1254,
63,
1178
],
[
1178,
40,
9
]
],
[
[
1254,
63,
401
],
[
401,
24,
9
]
],
[
[
1254,
63,
1630
],
[
1630,
1... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triflu... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may caus... |
DB00673 | DB00705 | 723 | 441 | [
"DDInter112",
"DDInter496"
] | Aprepitant | Delavirdine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Moderate | 1 | [
[
[
723,
24,
441
]
],
[
[
723,
6,
21998
],
[
21998,
45,
441
]
],
[
[
723,
21,
28709
],
[
28709,
60,
441
]
],
[
[
723,
63,
63
],
[
63,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound ... | Aprepitant (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Delavirdine (Compound)
Aprepitant (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseas... |
DB06212 | DB09039 | 165 | 1,670 | [
"DDInter1833",
"DDInter629"
] | Tolvaptan | Eliglustat | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
165,
24,
1670
]
],
[
[
165,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
165,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
165,
63,
322
],
[
322,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Tolvaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"... | Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cau... |
DB00065 | DB00262 | 581 | 552 | [
"DDInter923",
"DDInter302"
] | Infliximab | Carmustine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Major | 2 | [
[
[
581,
25,
552
]
],
[
[
581,
25,
377
],
[
377,
63,
552
]
],
[
[
581,
24,
697
],
[
697,
63,
552
]
],
[
[
581,
64,
305
],
[
305,
24,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carmustine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may... | Infliximab may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may ca... |
DB09075 | DB11793 | 498 | 738 | [
"DDInter621",
"DDInter1297"
] | Edoxaban | Niraparib | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
498,
24,
738
]
],
[
[
498,
64,
1213
],
[
1213,
24,
738
]
],
[
[
498,
25,
1033
],
[
1033,
63,
738
]
],
[
[
498,
63,
759
],
[
759,
... | [
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Edoxaban may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Edoxaban may lead to a major life threatening interaction when taken with Alpelisib and Alpelisib may cause a moderate interaction t... |
DB01268 | DB06288 | 1,151 | 607 | [
"DDInter1731",
"DDInter77"
] | Sunitinib | Amisulpride | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1151,
25,
607
]
],
[
[
1151,
21,
28785
],
[
28785,
60,
607
]
],
[
[
1151,
62,
112
],
[
112,
23,
607
]
],
[
[
1151,
63,
1559
],
[
1559,... | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Sunitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Muscle spasms"
],
[
"Muscle spasms",
"{u} (Side Effect) is caused by {v... | Sunitinib (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Amisulpride (Compound)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken wit... |
DB00065 | DB00900 | 581 | 45 | [
"DDInter923",
"DDInter544"
] | Infliximab | Didanosine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
581,
24,
45
]
],
[
[
581,
25,
36
],
[
36,
63,
45
]
],
[
[
581,
63,
491
],
[
491,
24,
45
]
],
[
[
581,
25,
482
],
[
482,
24,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
... | Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Didanosine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon ... |
DB00026 | DB08871 | 1,184 | 36 | [
"DDInter94",
"DDInter666"
] | Anakinra | Eribulin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1184,
24,
36
]
],
[
[
1184,
24,
221
],
[
221,
63,
36
]
],
[
[
1184,
24,
1463
],
[
1463,
24,
36
]
],
[
[
1184,
23,
1461
],
[
1461,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formal... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Anakinra may cause a moderate in... |
DB00445 | DB12141 | 322 | 971 | [
"DDInter655",
"DDInter817"
] | Epirubicin | Gilteritinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
322,
24,
971
]
],
[
[
322,
23,
1247
],
[
1247,
23,
971
]
],
[
[
322,
24,
485
],
[
485,
24,
971
]
],
[
[
322,
24,
730
],
[
730,
6... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine... |
DB00193 | DB00501 | 534 | 752 | [
"DDInter1841",
"DDInter380"
] | Tramadol | Cimetidine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
534,
24,
752
]
],
[
[
534,
6,
8374
],
[
8374,
45,
752
]
],
[
[
534,
21,
29134
],
[
29134,
60,
752
]
],
[
[
534,
23,
112
],
[
112,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cimetidine (Compound)
Tramadol (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB00307 | DB01097 | 1,101 | 1,377 | [
"DDInter202",
"DDInter1033"
] | Bexarotene | Leflunomide | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1101,
25,
1377
]
],
[
[
1101,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
1101,
21,
30543
],
[
30543,
60,
1377
]
],
[
[
1101,
24,
949
],
[
94... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflun... | Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Bexarotene (Compound) causes Skin nodule (Side Effect) and Skin nodule (Side Effect) is caused by Leflunomide (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Clostridium t... |
DB00356 | DB11186 | 1,315 | 1,609 | [
"DDInter366",
"DDInter1427"
] | Chlorzoxazone | Pentoxyverine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1315,
24,
1609
]
],
[
[
1315,
24,
649
],
[
649,
24,
1609
]
],
[
[
1315,
63,
701
],
[
701,
24,
1609
]
],
[
[
1315,
64,
475
],
[
475,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine a... |
DB00281 | DB00683 | 608 | 1,382 | [
"DDInter1066",
"DDInter1212"
] | Lidocaine | Midazolam | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
608,
24,
1382
]
],
[
[
608,
24,
1216
],
[
1216,
40,
1382
]
],
[
[
608,
63,
905
],
[
905,
40,
1382
]
],
[
[
608,
6,
8374
],
[
8374,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Midazolam (Compound)
Lidoca... |
DB00808 | DB01169 | 1,605 | 57 | [
"DDInter916",
"DDInter120"
] | Indapamide | Arsenic trioxide | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
1605,
25,
57
]
],
[
[
1605,
6,
8374
],
[
8374,
45,
57
]
],
[
[
1605,
24,
603
],
[
603,
63,
57
]
],
[
[
1605,
24,
480
],
[
480,
2... | [
[
[
"Indapamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Indapamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"A... | Indapamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic t... |
DB01234 | DB11986 | 1,220 | 484 | [
"DDInter513",
"DDInter648"
] | Dexamethasone | Entrectinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1220,
25,
484
]
],
[
[
1220,
23,
271
],
[
271,
23,
484
]
],
[
[
1220,
25,
466
],
[
466,
62,
484
]
],
[
[
1220,
24,
1135
],
[
1135,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirab... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may... |
DB01577 | DB09472 | 1,529 | 1,383 | [
"DDInter1161",
"DDInter1693"
] | Metamfetamine | Sodium sulfate | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1529,
24,
1383
]
],
[
[
1529,
75,
1466
],
[
1466,
24,
1383
]
],
[
[
1529,
63,
104
],
[
104,
24,
1383
]
],
[
[
1529,
1,
633
],
[
633,
... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {... | Metamfetamine (Compound) resembles Phenylpropanolamine (Compound) and Metamfetamine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Metamfetamine may cause a modera... |
DB00862 | DB09020 | 1,005 | 28 | [
"DDInter1918",
"DDInter212"
] | Vardenafil | Bisacodyl | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1005,
24,
28
]
],
[
[
1005,
21,
28666
],
[
28666,
60,
28
]
],
[
[
1005,
24,
823
],
[
823,
63,
28
]
],
[
[
1005,
25,
982
],
[
982,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Vardenafil",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
... | Vardenafil (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacer... |
DB01232 | DB11363 | 1,327 | 1,276 | [
"DDInter1640",
"DDInter39"
] | Saquinavir | Alectinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
1327,
24,
1276
]
],
[
[
1327,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
1327,
24,
850
],
[
850,
24,
1276
]
],
[
[
1327,
64,
1424
],
[
1424... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod"... | Saquinavir may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab v... |
DB01182 | DB08868 | 371 | 1,011 | [
"DDInter1534",
"DDInter737"
] | Propafenone | Fingolimod | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
371,
25,
1011
]
],
[
[
371,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
371,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
371,
62,
112
],
[
112,... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingo... | Propafenone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Propafenone (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Metronid... |
DB00227 | DB12130 | 1,463 | 1,017 | [
"DDInter1098",
"DDInter1094"
] | Lovastatin | Lorlatinib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1463,
24,
1017
]
],
[
[
1463,
24,
1101
],
[
1101,
23,
1017
]
],
[
[
1463,
24,
14
],
[
14,
24,
1017
]
],
[
[
1463,
63,
837
],
[
837,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuva... |
DB00031 | DB00407 | 20 | 202 | [
"DDInter1764",
"DDInter115"
] | Tenecteplase | Ardeparin | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Major | 2 | [
[
[
20,
25,
202
]
],
[
[
20,
24,
738
],
[
738,
63,
202
]
],
[
[
20,
24,
1595
],
[
1595,
24,
202
]
],
[
[
20,
25,
1564
],
[
1564,
64,... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Nirapari... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ardeparin
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostrid... |
DB05528 | DB12010 | 1,070 | 214 | [
"DDInter1228",
"DDInter785"
] | Mipomersen | Fostamatinib | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
1070,
25,
214
]
],
[
[
1070,
64,
866
],
[
866,
24,
214
]
],
[
[
1070,
25,
1250
],
[
1250,
24,
214
]
],
[
[
1070,
25,
159
],
[
159,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{... | Mipomersen may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mipomersen may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate in... |
DB01142 | DB01215 | 1,264 | 1,418 | [
"DDInter593",
"DDInter677"
] | Doxepin | Estazolam | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
1264,
24,
1418
]
],
[
[
1264,
63,
1216
],
[
1216,
40,
1418
]
],
[
[
1264,
24,
481
],
[
481,
40,
1418
]
],
[
[
1264,
63,
1119
],
[
1119... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Fl... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Estazolam (Compound)
Doxepin may ... |
DB00808 | DB13142 | 1,605 | 841 | [
"DDInter916",
"DDInter274"
] | Indapamide | Calcium glubionate anhydrous | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1605,
24,
841
]
],
[
[
1605,
23,
1669
],
[
1669,
24,
841
]
],
[
[
1605,
62,
1545
],
[
1545,
24,
841
]
],
[
[
1605,
40,
811
],
[
811,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline... | Indapamide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Indapamide may cause a minor interaction that can limit clinical effects when taken with Oxyte... |
DB00035 | DB00687 | 1,314 | 870 | [
"DDInter507",
"DDInter747"
] | Desmopressin | Fludrocortisone | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Major | 2 | [
[
[
1314,
25,
870
]
],
[
[
1314,
25,
1220
],
[
1220,
40,
870
]
],
[
[
1314,
21,
29180
],
[
29180,
60,
870
]
],
[
[
1314,
24,
1148
],
[
114... | [
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone... | Desmopressin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Desmopressin (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fludrocortisone (Compound)
Desmopressin may ... |
DB00563 | DB08870 | 663 | 850 | [
"DDInter1174",
"DDInter228"
] | Methotrexate | Brentuximab vedotin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
663,
24,
850
]
],
[
[
663,
24,
788
],
[
788,
24,
850
]
],
[
[
663,
25,
1338
],
[
1338,
24,
850
]
],
[
[
663,
24,
496
],
[
496,
6... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Methotrexate may lead to a major life threatening interaction when taken with Meclofenamic acid a... |
DB08820 | DB08893 | 1,478 | 271 | [
"DDInter997",
"DDInter1229"
] | Ivacaftor | Mirabegron | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Minor | 0 | [
[
[
1478,
23,
271
]
],
[
[
1478,
6,
1829
],
[
1829,
45,
271
]
],
[
[
1478,
21,
28722
],
[
28722,
60,
271
]
],
[
[
1478,
25,
129
],
[
129,
... | [
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ivacaftor",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Mi... | Ivacaftor (Compound) binds ALB (Gene) and ALB (Gene) is bound by Mirabegron (Compound)
Ivacaftor (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Mirabegron (Compound)
Ivacaftor may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor i... |
DB00631 | DB10276 | 372 | 1,624 | [
"DDInter405",
"DDInter1623"
] | Clofarabine | Rotavirus vaccine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
372,
25,
1624
]
],
[
[
372,
63,
552
],
[
552,
25,
1624
]
],
[
[
372,
24,
1307
],
[
1307,
25,
1624
]
],
[
[
372,
25,
770
],
[
770,
... | [
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"C... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may... |
DB00581 | DB00638 | 355 | 1,078 | [
"DDInter1018",
"DDInter950"
] | Lactulose | Inulin | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function. | Moderate | 1 | [
[
[
355,
24,
1078
]
],
[
[
355,
23,
16
],
[
16,
62,
1078
]
],
[
[
355,
24,
721
],
[
721,
62,
16
],
[
16,
62,
1078
]
],
[
[
355,
24,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Inulin"
]
],
[
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
[
"Li... | Lactulose may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Inulin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Methylcellulose and Methylcel... |
DB00570 | DB01155 | 147 | 872 | [
"DDInter1936",
"DDInter813"
] | Vinblastine | Gemifloxacin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Minor | 0 | [
[
[
147,
23,
872
]
],
[
[
147,
23,
739
],
[
739,
1,
872
]
],
[
[
147,
62,
1467
],
[
1467,
1,
872
]
],
[
[
147,
23,
945
],
[
945,
40,... | [
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Gemifloxacin (Compound... |
DB01618 | DB04837 | 776 | 649 | [
"DDInter1239",
"DDInter407"
] | Molindone | Clofedanol | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
776,
24,
649
]
],
[
[
776,
63,
1376
],
[
1376,
24,
649
]
],
[
[
776,
63,
832
],
[
832,
40,
649
]
],
[
[
776,
24,
1511
],
[
1511,
... | [
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[... | Molindone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamin... |
DB00443 | DB00731 | 251 | 1,144 | [
"DDInter195",
"DDInter1269"
] | Betamethasone | Nateglinide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
251,
24,
1144
]
],
[
[
251,
24,
610
],
[
610,
24,
1144
]
],
[
[
251,
6,
8374
],
[
8374,
45,
1144
]
],
[
[
251,
21,
28787
],
[
28787,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nateglinide (Compound)
Betamethason... |
DB00851 | DB09074 | 611 | 1,362 | [
"DDInter463",
"DDInter1327"
] | Dacarbazine | Olaparib | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
611,
24,
1362
]
],
[
[
611,
63,
896
],
[
896,
24,
1362
]
],
[
[
611,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
611,
24,
385
],
[
385,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekin... |
DB12130 | DB13879 | 1,017 | 1,043 | [
"DDInter1094",
"DDInter824"
] | Lorlatinib | Glecaprevir | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
1017,
24,
1043
]
],
[
[
1017,
63,
1135
],
[
1135,
23,
1043
]
],
[
[
1017,
25,
466
],
[
466,
24,
1043
]
],
[
[
1017,
64,
594
],
[
594,
... | [
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Lorlatinib may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause... |
DB00468 | DB04844 | 1,424 | 843 | [
"DDInter1557",
"DDInter1778"
] | Quinine | Tetrabenazine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1424,
24,
843
]
],
[
[
1424,
23,
479
],
[
479,
40,
843
]
],
[
[
1424,
6,
12523
],
[
12523,
45,
843
]
],
[
[
1424,
18,
3106
],
[
3106,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"D... | Quinine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Quinine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Quinine (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is do... |
DB04932 | DB06209 | 1,564 | 256 | [
"DDInter491",
"DDInter1508"
] | Defibrotide | Prasugrel | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
1564,
25,
256
]
],
[
[
1564,
23,
944
],
[
944,
62,
256
]
],
[
[
1564,
63,
901
],
[
901,
24,
256
]
],
[
[
1564,
24,
1427
],
[
1427,
... | [
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Defibrotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Defibrotide may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipra... |
DB01132 | DB01155 | 1,130 | 872 | [
"DDInter1472",
"DDInter813"
] | Pioglitazone | Gemifloxacin | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Moderate | 1 | [
[
[
1130,
24,
872
]
],
[
[
1130,
63,
739
],
[
739,
1,
872
]
],
[
[
1130,
24,
945
],
[
945,
40,
872
]
],
[
[
1130,
24,
1539
],
[
1539,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemiflox... |
DB00656 | DB01128 | 827 | 918 | [
"DDInter1851",
"DDInter204"
] | Trazodone | Bicalutamide | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
827,
24,
918
]
],
[
[
827,
24,
129
],
[
129,
40,
918
]
],
[
[
827,
6,
8374
],
[
8374,
45,
918
]
],
[
[
827,
21,
28642
],
[
28642,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Trazodone (Compound) causes Shock (Side Effect) and Shock (S... |
DB00197 | DB00734 | 1,324 | 1,664 | [
"DDInter1881",
"DDInter1605"
] | Troglitazone | Risperidone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
1324,
24,
1664
]
],
[
[
1324,
24,
924
],
[
924,
40,
1664
]
],
[
[
1324,
24,
1616
],
[
1616,
63,
1664
]
],
[
[
1324,
24,
888
],
[
888,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that ... |
DB00495 | DB01229 | 139 | 973 | [
"DDInter1961",
"DDInter1378"
] | Zidovudine | Paclitaxel (protein-bound) | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
139,
24,
973
]
],
[
[
139,
24,
310
],
[
310,
63,
973
]
],
[
[
139,
6,
8374
],
[
8374,
45,
973
]
],
[
[
139,
21,
28803
],
[
28803,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Zidovudi... |
DB09039 | DB09075 | 1,670 | 498 | [
"DDInter629",
"DDInter621"
] | Eliglustat | Edoxaban | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1670,
25,
498
]
],
[
[
1670,
64,
109
],
[
109,
24,
498
]
],
[
[
1670,
63,
1237
],
[
1237,
24,
498
]
],
[
[
1670,
24,
1017
],
[
1017,
... | [
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may... | Eliglustat may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may caus... |
DB06603 | DB13074 | 39 | 877 | [
"DDInter1387",
"DDInter1110"
] | Panobinostat | Macimorelin | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
39,
25,
877
]
],
[
[
39,
62,
112
],
[
112,
23,
877
]
],
[
[
39,
24,
1320
],
[
1320,
24,
877
]
],
[
[
39,
64,
1479
],
[
1479,
24,... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and E... |
DB00916 | DB08868 | 112 | 1,011 | [
"DDInter1202",
"DDInter737"
] | Metronidazole | Fingolimod | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Minor | 0 | [
[
[
112,
23,
1011
]
],
[
[
112,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
112,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
112,
23,
1247
],
[
1247,... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Metronidazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Metronidazole may cause a minor interaction that can limit clinical effe... |
DB00399 | DB09133 | 963 | 1,527 | [
"DDInter1968",
"DDInter965"
] | Zoledronic acid | Iothalamic acid | Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors,... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
963,
25,
1527
]
],
[
[
963,
24,
589
],
[
589,
25,
1527
]
],
[
[
963,
1,
1199
],
[
1199,
25,
1527
]
],
[
[
963,
40,
641
],
[
641,
... | [
[
[
"Zoledronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
... | Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Iothalamic acid
Zoledronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may lead to a major life threatening intera... |
DB00060 | DB00631 | 912 | 372 | [
"DDInter947",
"DDInter405"
] | Interferon beta-1a | Clofarabine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
912,
24,
372
]
],
[
[
912,
24,
1064
],
[
1064,
25,
372
]
],
[
[
912,
24,
595
],
[
595,
24,
372
]
],
[
[
912,
24,
725
],
[
725,
6... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide and Eth... |
DB01229 | DB15091 | 973 | 676 | [
"DDInter1377",
"DDInter1901"
] | Paclitaxel | Upadacitinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
973,
25,
676
]
],
[
[
973,
63,
1461
],
[
1461,
23,
676
]
],
[
[
973,
24,
1430
],
[
1430,
24,
676
]
],
[
[
973,
63,
1249
],
[
1249,
... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB00959 | DB01170 | 1,486 | 1,150 | [
"DDInter1191",
"DDInter846"
] | Methylprednisolone | Guanethidine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1486,
24,
1150
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
1150
]
],
[
[
1486,
24,
1344
],
[
1344,
63,
1150
]
],
[
[
1486,
1,
617
],
[
617,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound b... | Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanethidine (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Guane... |
DB00056 | DB00108 | 816 | 1,066 | [
"DDInter814",
"DDInter1268"
] | Gemtuzumab ozogamicin | Natalizumab | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Major | 2 | [
[
[
816,
25,
1066
]
],
[
[
816,
24,
949
],
[
949,
63,
1066
]
],
[
[
816,
25,
375
],
[
375,
64,
1066
]
],
[
[
816,
24,
738
],
[
738,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani ... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Natalizumab
... |
DB00460 | DB00682 | 612 | 126 | [
"DDInter1929",
"DDInter1951"
] | Verteporfin | Warfarin | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
612,
24,
126
]
],
[
[
612,
24,
663
],
[
663,
23,
126
]
],
[
[
612,
24,
918
],
[
918,
62,
126
]
],
[
[
612,
24,
1195
],
[
1195,
2... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bi... |
DB00095 | DB00322 | 66 | 141 | [
"DDInter623",
"DDInter742"
] | Efalizumab | Floxuridine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Moderate | 1 | [
[
[
66,
24,
141
]
],
[
[
66,
24,
1083
],
[
1083,
40,
141
]
],
[
[
66,
25,
1064
],
[
1064,
25,
141
]
],
[
[
66,
24,
611
],
[
611,
63,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) resembles Floxuridine (Compound)
Efalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when... |
DB01105 | DB13139 | 222 | 1,032 | [
"DDInter1665",
"DDInter1063"
] | Sibutramine | Levosalbutamol | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
222,
24,
1032
]
],
[
[
222,
24,
1618
],
[
1618,
24,
1032
]
],
[
[
222,
64,
121
],
[
121,
24,
1032
]
],
[
[
222,
25,
22
],
[
22,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Sibutramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluram... |
DB00308 | DB00983 | 347 | 480 | [
"DDInter901",
"DDInter776"
] | Ibutilide | Formoterol | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
347,
24,
480
]
],
[
[
347,
25,
1148
],
[
1148,
63,
480
]
],
[
[
347,
21,
29170
],
[
29170,
60,
480
]
],
[
[
347,
25,
1424
],
[
1424,
... | [
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenali... | Ibutilide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Ibutilide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused ... |
DB03404 | DB09075 | 765 | 498 | [
"DDInter855",
"DDInter621"
] | Hemin | Edoxaban | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
765,
24,
498
]
],
[
[
765,
64,
697
],
[
697,
24,
498
]
],
[
[
765,
24,
1496
],
[
1496,
63,
498
]
],
[
[
765,
63,
383
],
[
383,
2... | [
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Hemin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
... | Hemin may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a mode... |
DB01320 | DB04868 | 651 | 478 | [
"DDInter783",
"DDInter1293"
] | Fosphenytoin | Nilotinib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
651,
25,
478
]
],
[
[
651,
24,
1468
],
[
1468,
63,
478
]
],
[
[
651,
6,
6017
],
[
6017,
45,
478
]
],
[
[
651,
21,
28762
],
[
28762,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatini... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Fosphenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Fosphenytoin (Comp... |
DB00039 | DB00262 | 1,253 | 552 | [
"DDInter1380",
"DDInter302"
] | Palifermin | Carmustine | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Moderate | 1 | [
[
[
1253,
24,
552
]
],
[
[
1253,
24,
377
],
[
377,
63,
552
]
],
[
[
1253,
24,
599
],
[
599,
24,
552
]
],
[
[
1253,
24,
1064
],
[
1064,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuz... |
DB00619 | DB00731 | 1,419 | 1,144 | [
"DDInter909",
"DDInter1269"
] | Imatinib | Nateglinide | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1419,
24,
1144
]
],
[
[
1419,
63,
80
],
[
80,
40,
1144
]
],
[
[
1419,
24,
136
],
[
136,
40,
1144
]
],
[
[
1419,
6,
6943
],
[
6943,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Nateglinide (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide and Lacosamide (Compound) resembles Nateglinide (Compound)
... |
DB01075 | DB10429 | 1,376 | 200 | [
"DDInter569",
"DDInter282"
] | Diphenhydramine | Candida albicans | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1376,
24,
200
]
],
[
[
1376,
63,
701
],
[
701,
24,
200
]
],
[
[
1376,
74,
662
],
[
662,
24,
200
]
],
[
[
1376,
24,
478
],
[
478,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Diphenhydramine (Compound) resembles Carbinoxamine (Compound) and Diphenhydramine may cause a moderat... |
DB00352 | DB00963 | 482 | 1,263 | [
"DDInter1814",
"DDInter241"
] | Tioguanine | Bromfenac | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Moderate | 1 | [
[
[
482,
24,
1263
]
],
[
[
482,
24,
935
],
[
935,
40,
1263
]
],
[
[
482,
63,
831
],
[
831,
40,
1263
]
],
[
[
482,
24,
1512
],
[
1512,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bromfenac (Compound... |
DB04861 | DB11126 | 1,592 | 900 | [
"DDInter1271",
"DDInter276"
] | Nebivolol | Calcium gluconate | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
1592,
24,
900
]
],
[
[
1592,
5,
11590
],
[
11590,
44,
729
],
[
729,
24,
900
]
],
[
[
1592,
6,
8742
],
[
8742,
45,
729
],
[
729,
24,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Nebivolol",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is t... | Nebivolol (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Nebivolol (Compound) binds HTR1A (Gene) and HTR1A (Gene) is bound by Penbutolol (Compound) an... |
DB01024 | DB10276 | 1,096 | 1,624 | [
"DDInter1252",
"DDInter1623"
] | Mycophenolic acid | Rotavirus vaccine | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1096,
25,
1624
]
],
[
[
1096,
25,
375
],
[
375,
25,
1624
]
],
[
[
1096,
63,
58
],
[
58,
25,
1624
]
],
[
[
1096,
24,
270
],
[
270,
... | [
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
... | Mycophenolic acid may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and ... |
DB00556 | DB01069 | 1,262 | 401 | [
"DDInter1429",
"DDInter1533"
] | Perflutren | Promethazine | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1262,
24,
401
]
],
[
[
1262,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1262,
21,
29169
],
[
29169,
60,
401
]
],
[
[
1262,
24,
286
],
[
286,... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Perflutren (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Promethazine (Compound)
... |
DB01087 | DB08868 | 1,520 | 1,011 | [
"DDInter1520",
"DDInter737"
] | Primaquine | Fingolimod | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1520,
25,
1011
]
],
[
[
1520,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1520,
21,
28852
],
[
28852,
60,
1011
]
],
[
[
1520,
62,
1247
],
[
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingoli... | Primaquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Primaquine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Fingolimod (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole an... |
DB00006 | DB00176 | 942 | 529 | [
"DDInter217",
"DDInter770"
] | Bivalirudin | Fluvoxamine | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Moderate | 1 | [
[
[
942,
24,
529
]
],
[
[
942,
25,
20
],
[
20,
24,
529
]
],
[
[
942,
24,
1274
],
[
1274,
63,
529
]
],
[
[
942,
25,
1421
],
[
1421,
6... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenec... | Bivalirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen... |
DB00445 | DB14443 | 322 | 987 | [
"DDInter655",
"DDInter1931"
] | Epirubicin | Vibrio cholerae CVD 103-HgR strain live antigen | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
322,
24,
987
]
],
[
[
322,
24,
1480
],
[
1480,
24,
987
]
],
[
[
322,
63,
141
],
[
141,
24,
987
]
],
[
[
322,
25,
351
],
[
351,
2... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Epirubicin may cause a moderate interaction that could exacerbate diseases when... |
DB01255 | DB13074 | 633 | 877 | [
"DDInter1078",
"DDInter1110"
] | Lisdexamfetamine | Macimorelin | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
633,
25,
877
]
],
[
[
633,
62,
112
],
[
112,
23,
877
]
],
[
[
633,
24,
913
],
[
913,
24,
877
]
],
[
[
633,
63,
770
],
[
770,
24,... | [
[
[
"Lisdexamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Apalut... |
DB00818 | DB11110 | 898 | 603 | [
"DDInter1538",
"DDInter1115"
] | Propofol | Magnesium citrate | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
898,
24,
603
]
],
[
[
898,
24,
57
],
[
57,
24,
603
]
],
[
[
898,
24,
484
],
[
484,
63,
603
]
],
[
[
898,
63,
1424
],
[
1424,
24,... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
],... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Entrec... |
DB00622 | DB09133 | 1,081 | 1,527 | [
"DDInter1287",
"DDInter965"
] | Nicardipine | Iothalamic acid | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
1081,
24,
1527
]
],
[
[
1081,
24,
278
],
[
278,
63,
1527
]
],
[
[
1081,
40,
84
],
[
84,
24,
1527
]
],
[
[
1081,
24,
512
],
[
512,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Nicardipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interacti... |
DB00443 | DB12095 | 251 | 179 | [
"DDInter195",
"DDInter1760"
] | Betamethasone | Telotristat ethyl | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
251,
24,
179
]
],
[
[
251,
24,
1517
],
[
1517,
24,
179
]
],
[
[
251,
24,
283
],
[
283,
63,
179
]
],
[
[
251,
25,
593
],
[
593,
2... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fedr... |
DB00284 | DB00436 | 1,647 | 323 | [
"DDInter11",
"DDInter179"
] | Acarbose | Bendroflumethiazide | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Moderate | 1 | [
[
[
1647,
24,
323
]
],
[
[
1647,
24,
1014
],
[
1014,
1,
323
]
],
[
[
1647,
21,
28680
],
[
28680,
60,
323
]
],
[
[
1647,
23,
126
],
[
126,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Acarbose (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Bendroflumethiazide (Compound)
Acarbose may cause a minor interacti... |
DB00604 | DB01182 | 1,425 | 371 | [
"DDInter385",
"DDInter1534"
] | Cisapride | Propafenone | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Major | 2 | [
[
[
1425,
25,
371
]
],
[
[
1425,
64,
847
],
[
847,
1,
371
]
],
[
[
1425,
25,
675
],
[
675,
40,
371
]
],
[
[
1425,
24,
455
],
[
455,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Propafenone"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} ... | Cisapride may lead to a major life threatening interaction when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Cisapride may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Propafenone (Compound)
Cisapride ma... |
DB00775 | DB01105 | 1,226 | 222 | [
"DDInter1818",
"DDInter1665"
] | Tirofiban | Sibutramine | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1226,
24,
222
]
],
[
[
1226,
21,
28845
],
[
28845,
60,
222
]
],
[
[
1226,
25,
802
],
[
802,
63,
222
]
],
[
[
1226,
63,
1027
],
[
1027,... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Tirofiban",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {... | Tirofiban (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Sibutramine (Compound)
Tirofiban may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Tirofiban may cau... |
DB00612 | DB09564 | 1,121 | 1,296 | [
"DDInter216",
"DDInter930"
] | Bisoprolol | Insulin degludec | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1121,
24,
1296
]
],
[
[
1121,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1121,
62,
542
],
[
542,
24,
1296
]
],
[
[
1121,
1,
88
],
[
88,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine a... |
DB00744 | DB11730 | 1,288 | 351 | [
"DDInter1962",
"DDInter1588"
] | Zileuton | Ribociclib | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1288,
24,
351
]
],
[
[
1288,
24,
283
],
[
283,
62,
351
]
],
[
[
1288,
63,
372
],
[
372,
24,
351
]
],
[
[
1288,
24,
1613
],
[
1613,
... | [
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine... |
DB00912 | DB01203 | 473 | 699 | [
"DDInter1581",
"DDInter1255"
] | Repaglinide | Nadolol | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
473,
24,
699
]
],
[
[
473,
24,
729
],
[
729,
1,
699
]
],
[
[
473,
21,
28722
],
[
28722,
60,
699
]
],
[
[
473,
63,
1152
],
[
1152,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Repaglinide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Nadolol (Compound)
Repaglinide may cause a moderate interaction that coul... |
DB00414 | DB06791 | 590 | 1,446 | [
"DDInter16",
"DDInter1021"
] | Acetohexamide | Lanreotide | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
590,
24,
1446
]
],
[
[
590,
24,
154
],
[
154,
63,
1446
]
],
[
[
590,
24,
887
],
[
887,
24,
1446
]
],
[
[
590,
63,
461
],
[
461,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pi... |
DB00191 | DB00652 | 73 | 234 | [
"DDInter1447",
"DDInter1421"
] | Phentermine | Pentazocine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
73,
24,
234
]
],
[
[
73,
21,
28662
],
[
28662,
60,
234
]
],
[
[
73,
24,
1264
],
[
1264,
63,
234
]
],
[
[
73,
24,
999
],
[
999,
2... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused ... | Phentermine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Pentazocine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine
Phen... |
DB01359 | DB06705 | 729 | 1,106 | [
"DDInter1417",
"DDInter795"
] | Penbutolol | Gadofosveset trisodium | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of th... | Moderate | 1 | [
[
[
729,
24,
1106
]
],
[
[
729,
21,
28645
],
[
28645,
60,
1106
]
],
[
[
729,
40,
461
],
[
461,
24,
1106
]
],
[
[
729,
1,
699
],
[
699,
... | [
[
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
]
],
[
[
"Penbutolol",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is ... | Penbutolol (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Gadofosveset trisodium (Compound)
Penbutolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium
Penbutolol (Compound) resembles Na... |
DB08864 | DB12500 | 786 | 283 | [
"DDInter1595",
"DDInter714"
] | Rilpivirine | Fedratinib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
786,
24,
283
]
],
[
[
786,
25,
351
],
[
351,
23,
283
]
],
[
[
786,
63,
1419
],
[
1419,
24,
283
]
],
[
[
786,
24,
951
],
[
951,
2... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rilpivirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocicl... | Rilpivirine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a mo... |
DB08870 | DB10429 | 850 | 200 | [
"DDInter228",
"DDInter282"
] | Brentuximab vedotin | Candida albicans | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
850,
24,
200
]
],
[
[
850,
63,
1683
],
[
1683,
24,
200
]
],
[
[
850,
25,
976
],
[
976,
24,
200
]
],
[
[
850,
64,
908
],
[
908,
2... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ust... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Brentuximab vedotin may lead to a major life threatening interaction when taken with Tofacitini... |
DB00060 | DB00289 | 912 | 847 | [
"DDInter947",
"DDInter132"
] | Interferon beta-1a | Atomoxetine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Moderate | 1 | [
[
[
912,
24,
847
]
],
[
[
912,
24,
109
],
[
109,
40,
847
]
],
[
[
912,
24,
126
],
[
126,
1,
847
]
],
[
[
912,
24,
609
],
[
609,
63,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Atomoxetine (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Atomoxeti... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.